NMN vs NR: which is better? No trial has compared them directly

The NMN vs NR question has no direct answer, because no trial has given one group NMN and another NR and then compared the two. What the research does establish is narrower: both compounds hit their biochemical target. A 2026 systematic review of intervention studies published between January 2010 and October 2025 found that oral NMN and NR consistently raised NAD+ and related molecules, measured in blood and in immune cells drawn from blood [2].

Of the 113 studies that review included, 80 were done in rodents. Thirty-three ran in people: 28 randomly assigned who received the supplement and who did not, and 5 did not randomise [2].

In the rodent studies, raising NAD+ often improved measures of metabolism, mitochondrial function and inflammation, though not in every model and not on every measure [2]. In people, that pattern did not hold. Effects on physical function, metabolism and blood vessel health went in different directions from trial to trial, and many trials found no difference at all [2]. The review's own verdict was that NAD+ supplements show clear biological activity and unproven clinical usefulness [2].

Healthy and athletic adults are where the record looks thinnest. A review of NAD+ supplements and muscle concluded that they do not change how skeletal muscle uses energy and do not improve athletic performance in healthy people, and that the benefits reported so far came from clinical situations where NAD+ was already depleted [6]. Its authors went further, and questioned whether testing these compounds in healthy populations is worth doing at all [6].

Safety looks solid, within the time frames that have been studied. Reviews of oral NMN and NR describe both as safe and well tolerated over weeks to months [1][2]. A benefit-risk review that screened 1,545 papers and included 147 of them, 113 in animals and 34 in people, found little short-term toxicity but listed three concerns that no long-term human trial has yet tested [3]:

• a build-up of potentially toxic by-products
• tumour growth
• more cells entering senescence, a worn-out state in which a cell stops dividing but does not die

The same review noted that long-term human trials in this field barely exist yet [3].

NAD+ works as part of the machinery rather than as a drug. Cells spend it in two ways: as a shuttle that carries electrons through the reactions that pull energy out of food, and as a consumable raw material for enzymes that repair DNA and switch genes on and off [8]. The best studied of those enzymes are the sirtuins, proteins that strip chemical tags off other proteins and cannot do it without NAD+, which is why NAD+ supply and sirtuin activity track each other [8].

NAD+ falls with age in both animals and people, and nobody has pinned down why: less of it is made, more of it is spent, or both [4][5]. Low NAD+ also turns up in diseased tissue. Failing heart muscle holds less of it [12], and so does brain tissue in Alzheimer's and Parkinson's disease [10].

Much of the proposed benefit runs through mitochondria, the compartments inside a cell that produce most of its energy. NAD+ helps regulate mitophagy, the process that marks damaged mitochondria and digests them so new ones can take their place [7][14]. When that clearance slows, broken mitochondria pile up, and that build-up is one of the recognised features of ageing tissue [14].

Swallowing NMN or NR adds raw material to this machinery, and blood tests confirm the material arrives [2]. The step the evidence has not completed is the one from a higher NAD+ reading to a body that measurably works better. A 2026 review of sirtuin-based approaches to immune ageing put NAD+ precursors in the investigational category, and judged drugs acting on mTOR, a separate pathway that controls cell growth, closer to clinical use [13].

The biggest numbers in this field come from animals, and they stay there. One review of NAD+ and male reproductive ageing reports that NMN restored sperm normality by 40%, in preclinical models rather than in men; the human data it cites amount to loose improvements in things like muscle function [11].

The evidence does not cover:

• healthy, trained adults, in whom NAD+ supplements did not alter muscle energy use or performance [6]
• anyone choosing between NMN and NR, since no trial has compared them
• injected NAD+, where a 2026 review found no eligible trial measuring a health outcome for anti-ageing or wellness use, only one non-randomised intravenous NMN study reporting short-term safety and biomarkers [2]
• anything past a few months, because the human trials ran weeks to months [2][3]

The human trials were also small, and doses and durations varied so much between them that the results cannot be sensibly combined into a single number [1]. The compounds sold as NAD+ boosters are not interchangeable either: nicotinamide and nicotinic acid, two other raw materials for NAD+, differ from NR and NMN both in how much they raise NAD+ and in which side effects they carry [5].

Picture two bottles on a shelf, one labelled NMN and one NR. The research cannot tell you which to choose, and it cannot tell you that either will change how you feel. It can tell you what a blood test would show: take either for a few weeks and your NAD+ reading would most likely be higher than when you started [2]. Whether a higher reading means anything for your strength or your arteries is the question those 33 human trials left open [2]. The one group that did gain something measurable was people whose NAD+ was low for a medical reason, not healthy adults topping up [6].